Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro(Children's Healthcare of Atlanta), Arzu Onar‐Thomas(St. Jude Children's Research Hospital), Tina Young Poussaint(Boston Children's Hospital), Shengjie Wu(St. Jude Children's Research Hospital), Azra H. Ligon(Harvard University), Neal I. Lindeman(Harvard University), Anuradha Banerjee(Center for Cancer and Blood Disorders), Roger J. Packer(Children's National), Lindsay Kilburn(Children's National), Stewart Goldman(Lurie Children's Hospital), Ian F. Pollack(Children's Hospital of Pittsburgh), Ibrahim Qaddoumi(St. Jude Children's Research Hospital), Regina I. Jakacki(Children's Hospital of Pittsburgh), Paul G. Fisher(Stanford University), Girish Dhall(Children's Hospital of Los Angeles), Patricia Baxter(Texas Children's Hospital), Susan G. Kreissman(Duke University), Clinton F. Stewart(St. Jude Children's Research Hospital), David Jones(German Cancer Research Center), Stefan M. Pfister(German Cancer Research Center), Gilbert Vézina(Children's National), Jessica Stern(Lurie Children's Hospital), Ashok Panigrahy(Children's Hospital of Pittsburgh), Zoltán Patay(St. Jude Children's Research Hospital), Benita Tamrazi(Children's Hospital of Los Angeles), Jeremy Jones(Nationwide Children's Hospital), Sofia Haque(Memorial Sloan Kettering Cancer Center), David S. Enterline(Duke University), Soonmee Cha(University of California, San Francisco), Michael J. Fisher(Children's Hospital of Philadelphia), L. Austin Doyle(National Cancer Institute), Malcolm A. Smith(National Cancer Institute), Ira J. Dunkel(Memorial Sloan Kettering Cancer Center), Maryam Fouladi(Cincinnati Children's Hospital Medical Center)
The Lancet Oncology
May 28, 2019
Cited by 497Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis